Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Danica Wilking

Obstetrics & Gynecology Newburgh, IN Medical Doctor

NPI 1366653602 CMS profile 288628

4199 Gateway Blvd, Suite 2500, Newburgh, IN 47630

Open in the dashboard

General payments

$4,250

239 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Danica Wilking of Newburgh, IN is reported in the CMS Open Payments database as having received $4,250 across 239 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 88th percentile of Obstetrics & Gynecology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $600 29
2024 General $412 22
2023 General $1,048 47
2022 General $752 47
2021 General $614 42
2020 General $334 22
2019 General $490 30

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Danica Wilking
  • Obstetrics & Gynecology median
  • Middle half of Obstetrics & Gynecology
  • National median

In program year 2025, general payments to Danica Wilking were reported at $600. Among 21,306 Obstetrics & Gynecology profiles paid that year, the median was $158 and the middle half received between $51 and $401.

Show as a table
Year Danica Wilking Obstetrics & Gynecology median Middle half National median
2019 $490 $172 $62–$391 $163
2020 $334 $94 $36–$222 $114
2021 $614 $136 $42–$369 $132
2022 $752 $160 $50–$433 $149
2023 $1,048 $169 $56–$423 $160
2024 $412 $152 $50–$371 $164
2025 $600 $158 $51–$401 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AbbVie, Inc. $810 49 payments
  2. Biogen, Inc. $327 14 payments
  3. Sumitomo Pharma America, Inc. $326 18 payments
  4. Mayne Pharma Inc. $293 18 payments
  5. Daiichi Sankyo Inc. $275 12 payments
  6. Avion Pharmaceuticals $266 21 payments
  7. Vermillion, Inc. $199 3 payments
  8. Shield Therapeutics Inc $188 10 payments
  9. Astellas Pharma US Inc $185 10 payments
  10. Myovant Sciences Inc. $154 9 payments
  11. Other $1,226 75 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $4,250 239 payments
Products named General payments · program years 2019–2025
  1. LO LOESTRIN FE $337 23 payments
  2. Zurzuvae $297 13 payments
  3. MYFEMBREE $277 16 payments
  4. INJECTAFER $255 11 payments
  5. ORILISSA Womens Health $231 15 payments
  6. OVA1 $199 3 payments
  7. ACCRUFER $188 10 payments
  8. Balcoltra $169 14 payments
  9. Orilissa Endocrinology $165 9 payments
  10. Veozah $152 8 payments
  11. Other $2,456 156 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 2 drugs

Part D claims

28

Median for Obstetrics & Gynecology: 65

Drug cost

$807

Median for Obstetrics & Gynecology: $3,585

Branded share of claims

0%

Median for Obstetrics & Gynecology: 25.1%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Estradiol Generic 12 $687
Paroxetine Hcl Generic 16 $120

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 24,311 Part D prescribers listed as Obstetrics & Gynecology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 7 billing codes

Paid by Medicare

$3,049

Medicare's payments for the services billed

Medicare patients

34

Average age 70

Services billed

76

34 women, 0 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 59%
Arthritis 44%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 6 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
MYFEMBREE
  • Sumitomo Pharma America, Inc. $52
$52 — —
Veozah
  • Astellas Pharma US Inc $48
$48 — —
SLYND
  • Exeltis, USA Inc. $31
$31 — —
GEMTESA
  • Sumitomo Pharma America, Inc. $19
$19 — —
Exparel
  • Pacira Pharmaceuticals Incorporated $16
$16 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 6 in the dashboard with a free account

Records

239 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record